Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany

The Juniper Germany digital weight-loss service delivers semaglutide alongside multidisciplinary team (MDT) support of doctors, university-qualified health coaches and nurse practitioners through an asynchronous, web-based web platform. Unlike the app-based Juniper UK and Australia programmes, patients log weight manually through a desktop portal rather than via Bluetooth-connected scales. This retrospective analysis is the first large-scale 12-month evaluation of a semaglutide-supported digital weight-loss services (DWLS) in Germany and it captures the gap between what the programme can deliver for adherent patients.

Among the 546 patients who consistently ordered medication and submitted weight data, the mean weight loss after 6 months was 11.62% and after 12 months was 15.13%.

91.2% of the adherent patients achieved ≥5% weight loss and 77.1% achieved ≥10% weight loss.

Medical history and tracking behaviour as predictors of programme adherence 

• A higher risk for attrition was found for patients with three or more comorbidities (OR=2.12, p=0.002) and those with a history of GLP-1 RA use (OR=1.62, p<0.001), suggesting that treatment-experienced patients have lower thresholds for discontinuation when early trajectories don't meet expectations. The authors therefore propose a more intensive, hybrid care combining asynchronous digital support with intermittent in-person assessment for patients with higher complexity profiles. 
• Patients who tracked their weight regularly (2–10 logs per month) had significantly lower churn risk than baseline-only trackers, while intensive tracking (>10 logs) showed no further benefit for persistence. This contrasts with Juniper UK and Australia cohorts, where intensive early tracking predicted higher churn. The authors hypothesise that because Germany's manual web-portal logging has higher behavioural friction than the app-based AU/UK programmes with Bluetooth scales, consistent tracking signals intentional commitment rather than anxiety.

What this means for digital obesity care

The findings reinforce a central tension in pharmacotherapy-integrated DWLS: Juniper’s DWLS supports patients in achieving clinically significant weight loss. German patients who consistently ordered medication and submitted weight data, achieved 15.13% weight loss over one year, underscoring that active programme engagement drives successful weight loss.

‍